Filing Flows

Filing Flows › Staar Surgical (STAA) › Q3 2026

Staar Surgical (STAA) Q3 2026 earnings results (third quarter 2026)

10-Q filed Nov 4, 2026

Staar Surgical (STAA) reported revenue of $83.4M for the third quarter 2026 (Q3 2026), -12% from a year earlier and -11% from the quarter before. Operating margin was 6.5%, net earnings $5.6M (6.7% of revenue).

Revenue$83.4M
Year over year-12%
Quarter over quarter-11%
Operating margin6.5%
Net earnings$5.6M

Staar Surgical, Q3 2026: revenue $83.4M (-12% year over year), operating margin 6.5%, net earnings $5.6M, operating cash flow $27.3M. The chart follows the revenue to costs, profit and cash.

Q3 2026AmountQ/QY/Y
Revenue$83.4M-11%-12%
Gross profit$59.1M-15%-24%
Operating profit$5.5M-46%-70%
Net earnings$5.6M-31%-37%
Operating cash flow$27.3M+39%+924%
Free cash flow$26.4M—15×

What changed

Revenue was $83.4M in Q3 2026, down 12% year over year and down 11% from the previous quarter.

Gross margin was 70.9%, down 11.3 points from Q3 2025. Operating profit was $5.5M, a 6.5% margin (down 13.0 points year over year). Operating expenses fell 10% while revenue fell 12%. Net earnings were $5.6M, down 37% year over year. The effective tax rate was 20.1%. Non-operating items added $1.5M, 22% of pre-tax earnings, so the bottom line overstates operating performance.

Operating cash flow was $27.3M (up 924% year over year), 490% of net earnings. Non-cash charges added back $2.4M of depreciation and $5.5M of share-based compensation. Working capital and other items added $13.8M. After acquisition of property and equipment ($935K), free cash flow as the company reports it was $26.4M.

Questions

What was Staar Surgical's revenue in the third quarter 2026?

Staar Surgical (STAA) reported revenue of $83.4M for the third quarter 2026 (Q3 2026), -12% from a year earlier and -11% from the quarter before.

Was Staar Surgical profitable in the third quarter 2026?

Operating profit was $5.5M (6.5% of revenue) and net earnings $5.6M.

Open the interactive Sankey →

Source: Staar Surgical 10-Q on SEC EDGAR.